Hot Safest Companies To Invest In 2014

Hot Safest Companies To Invest In 2014: Tetraphase Pharmaceuticals Inc (TTPH)

Tetraphase Pharmaceuticals, Inc., incorporated on July 7, 2006, is a clinical stage biopharmaceutical company. The Company's product candidate, eravacycline, is a fully synthetic tetracycline derivative that the Company are developing as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant Gram-negative infections. The Company's frequently used products, such as Zyvox and Cubicin, are limited to Gram-positive bacteria and thus are rarely used as a first-line empiric monotherapy if broad bacterial coverage is required. During the year ended December 31, 2012, completed a Phase 2 clinical trial of eravacycline with intravenous administration for the treatment of patients with complicated intra-abdominal infections, or cIAI, and are finalizing its pivotal Phase 3 program for eravacycline. In 2012, in vitro experiments, eravacycline has demonstrated the ability to cover a variety of multi-drug resistant Gram-negative, Gram-positive, anaerobic and atypical bacteria, including multi-drug resistant Klebsiella pneumoniae, the species of Gram-negative bacteria that killed seven patients at the Clinical Center of the National Institutes of Health.

Gram-positive bacteria that have developed resistance to existing drugs include: Streptococcus pneumoniae that cause pneumonia, ear infections, bloodstream infections and meningitis; Staphylococcus aureus that cause skin, bone, lung and bloodstream infections, and Enterococci that are responsible for infections transmitted in healthcare settings. Gram-negative bacteria that have developed resistance to existing drugs include: Escherichia coli that cause urinary tract, skin and bloodstream infections; Salmonella and Escherichia coli that cause foodborne i! nfections, and Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella spp.

In addition, other a ntibiotics that have been used as first-line empiric monothe! rapies, such as Levaquin, piperacillin/tazobactam, which is marketed by Pfizer as Zosyn, carbapenems, such as Merrem, and imipenem/cilastatin, which is marketed by Merck as Primaxin, have seen their utility as first-line empiric monotherapies diminished as the number of bacterial strains resistant to these therapies has increased. In addition to developing an intravenous formulation of eravacycline, the Company is also developing an oral formulation. A number of previous tetracyclines have been available in both intravenous and oral dosage forms. Infections that are resistant to existing oral drugs are increasingly common, and the Company believe that an intravenous-to-oral step-down therapy in which patients are started on the intravenous formulation of eravacycline and then stepped down to an oral formulation of eravacycline could reduce the length of a patient's hospital stay or help avoid hospital admission altogether, lowering the overall cost of care for these patien ts.

Advisors' Opinion:

• [By Roberto Pedone]

  Another under-$10 biopharmaceutical player that's starting to trend within range of triggering a near-term breakout trade is Tetraphase Pharmaceuticals (TTPH), which using its proprietary chemistry technology creates novel antibiotics for serious and life-threatening multi-drug resistant infections. This stock is off to a strong start in 2013, with shares up 19.4%.

  If you take a look at the chart for Tetraphase Pharmaceuticals, you'll notice that this stock has just started to trend back above its 50-day moving average of $7.76 a share with decent upside volume flows. That move is quickly pushing shares of TTPH within range of breaking out above some key near-term overhead resistance levels that have acted as a ceiling for the stock for the last three months.

  Mark! et player! s should now look for long-biased trades in TTPH if it manages to break out above some near-term overhead resistance levels at $8.30 to $8.40 a share and then once it takes out more resistance at $8.50 to $9 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average volume of 62,234 shares. If that breakout triggers soon, then TTPH will set up to re-test or possibly take out its all-time high at $9.66 a share. Any high-volume move above that level will then push TTPH into new all-time high territory, which is bullish technical price action. Some possible upside targets off that move are $12 to $13 a share.

  Traders can look to buy TTPH off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $7.76 a share, or below more key near-term support levels at $7.37 to $7.02 a share. One can also buy TTPH off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

source from Top Stocks Blog:http://www.topstocksblog.com/hot-safest-companies-to-invest-in-2014.html